Tempus AI stock forecast 2025 aligns with broader AI sector funding trends. Venture capital inflows into healthcare AI projects are projected to grow 30%, indirectly boosting Tempus AI’s valuation through expanded market credibility. iRhythm Technologies (IRTC) : Free Stock Analysis Report To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. Based on Q1 and Q2 performance metrics, Tempus AI stock forecast 2025 is supported by robust R&D investment. Analysts note the company's proprietary data algorithms could boost EPS growth by 15%-18% year-over-year, outperforming biotech-sector medians.